Introduction
GCN4 (but not HAP4) (Barlev et al., 1995) , and also with TBP (Barlev et al., 1995) . ADA2, ADA3 and GCN5 Activation of transcription by RNA polymerase II requires interacted with each other in vitro (Horiuchi et al., 1995) several classes of proteins that function in a coordinate and in vivo (Candau and Berger, 1996) , which argued manner (Tjian and Maniatis, 1994) . General factors constistrongly for the existence of a physiologically relevant tuting the basal transcription machinery recognize the ADA complex. Taken together, these data suggest that core promoter composed of the TATA box and adjacent the ADA complex bridges interactions between specific initiation site. They include RNA polymerase II and other activation domains and the general factors. factors (TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH) To activate transcription in vivo, the transcriptional required for initiation and elongation of mRNA (for machinery must overcome repression caused by associreviews, see Reinberg, 1993, 1995; Buratowski, ation of genes with nucleosomes, which requires chromatin 1994). Transcriptional activators bind to specific DNA reorganization (for a review, see Grunstein, 1990 ; Wolffe, sequences upstream of core promoters (Ptashne, 1986 (Ptashne, , 1994b Struhl, 1996) . Genetic approaches in yeast have 1988; Goodrich et al., 1996) and increase the rate of identified transcriptional regulators that appear to have transcription by the basal machinery.
evolved to deal with the repressive environment of Mechanisms of activation are not fully understood, chromatin. For example, the SWI-SNF complex alters although it is generally accepted that proteins distinct chromatin structure (Hirschhorn et al., 1992) and is from general factors and activators play a role (Guarente, 1995) . One class of proteins, often referred to as adaptors, required to enhance transcription by many transcriptional activators (Peterson and Herskowitz, 1992; Laurent et al., 1993) . In addition, the adaptor GCN5 has been shown to possess histone acetyltransferase (HAT) activity . Since hyperacetylation of amino-terminal tails of core histones correlates with the activity of certain genes (Csordas, 1990; Loidl, 1994; Wolffe, 1994a; Wolffe and Pruss, 1996) , the HAT activity of GCN5 suggests a link between nucleosome acetylation and transcriptional activation. Further evidence of the role of histone acetylation and deacetylation in the regulation of transcription in eukaryotes is the isolation of a mammalian histone deacetylase (Taunton et al., 1996) , related to the yeast transcriptional regulator Rpd3p (Vidal and Gaber, 1991) .
Recombinant GCN5 is able to acetylate histone H3 when present in a mixture of 'free' histones, but is unable to acetylate histones in nucleosomes (Kuo et al., 1996; Yang et al., 1996) . Complexes containing GCN5 in both Tetrahymena (J. Brownell and C.D.Allis, unpublished data) and yeast (P.Grant and J.Workman, personal communication) acetylate core histones in nucleosomes. One explanation for this difference is that additional components of the multi-subunit ADA complex are required for GCN5 to acetylate physiologically relevant, nucleosomal substrates. domain is required for growth and transcriptional activacatalytic regions I-IV as described in . Series 1: tion in vivo. These results directly link the HAT domain amino-termini and carboxy-termini deletions of GCN5 (Candau and Berger, 1996) . Full-length GCN5 comprises amino acids 1-440. to transcriptional activation in vivo and provide genetic Deleted versions of GCN5 are composed of residues: 1-350, 1-253, evidence that the ADA complex is required for GCN5 to 1-170, 95-253, 95-440, 170-350, 170-440 and 254-440 which are acetylate nucleosomal substrates in vivo.
shown relative to full-length. Series 2: carboxy-termini deletions of GCN5. Deleted versions of GCN5 are composed of residues 1-261, 1-280, 1-299 and 1-316.
Results

Mapping of the HAT domain in vitro
A series of deletions mutants which progressively delete from the amino-or carboxy-terminus of GCN5 have been Yeast GCN5 was divided into five subregions (Figure 1 , top) based on the degree of conservation between GCN5 described (Candau and Berger, 1996 ; Figure 1 , series 1), based on the conservation described above. To identify homologs identified in organisms ranging from yeast to humans, as follows: (A) the amino-terminus (amino acids the region possessing HAT activity in vitro, each of the deletion mutants was subcloned into a bacterial expression 1-95) is poorly conserved; (B) amino acids 95-170 are well conserved (64% similarity); (C) the region between plasmid, in-frame with a 'six-his' tag. Protein was induced, purified on nickel-agarose beads and similar amounts of amino acids 170 and 253 is highly conserved (88% similarity); (D) the region between amino acids 253 and each protein ( Figure 2A ) were separated on SDS-PAGE, polymerized in the presence of free histones for an 'in-350 is well conserved (55% similarity) and contains the region necessary for interaction with ADA2 (Candau et al., gel' HAT assay, as previously described Allis, 1995). 1996) ; and (E) the bromodomain (aa 350-440) has 57% similarity and is present in a variety of eukaryotic proteins Deletion of the first 95 amino acids (GCN5 ), or the last 90 amino acids, including the bromodomain having putative co-activator or adaptor function (Haynes et al., 1992) . We have argued previously, based solely (GCN5 1-350 ), had little effect on HAT activity ( Figure 2B and C) as compared with the wild-type enzyme prepared upon amino acid conservation between the yeast and Tetrahymena enzyme, that the region between amino acids under identical conditions. Deletion of the aminoterminal 170 amino acids (GCN5 ) 120 and 253 may constitute the enzymatic HAT domain, and have identified four extremely highly conserved subor the carboxy-terminal 190 amino acids (GCN5 1-253 ) reduced HAT activity to approximately one-quarter of regions (I-IV) . We have also proposed that the bromodomain may target HAT activity that of the full-length protein. Deletion of both ends (GCN5 ) reduced activity to 10% of wild-type. to chromatin 'receptors' , since yeast HAT1 (Kleff et al., 1995) , the cytoplasmic HAT, Thus, loss of sequences including the HAT subregion I (aa 120-140; Figure 1 ) reduced activity significantly, does not contain a bromodomain, although it does contain other sequence elements, presumably catalytic, in common but not completely. Mutants containing deletions between amino acids 170 and 253 (GCN5 254-440 and with GCN5 . In-gel histone acetyltransferase assay of the deletion peptides. Purified proteins (as shown in A) were analyzed by 8% SDS-PAGE and assayed for HAT activity as described previously (Brownell and Allis, 1995) . First, we tested the ability of each of the series 2 Internal deletions of each HAT subregion I-IV, mutants to acetylate histones in vitro (Figure 3) . A similar between amino acids 120 and 253 (Figure 1 ), were amount of each protein ( Figure 3A ) was compared with negative for HAT activity (data not shown). However, the full-length GCN5 or with GCN5 1-253 in the in-gel these proteins failed to interact with ADA2 (data not assay ( Figure 3B and C). As before, GCN5 1-253 had Ͻ25% shown), even though the region of interaction for ADA2 of wild-type activity, but the next largest peptide, GCN5 1-as previously determined (aa 254-350; Candau and 261 , had activity comparable with wild-type. Each of the Berger, 1996) was present. Thus, these mutant derivatives other, even larger peptides (aa 1-280, 1-299 and 1-316) were probably folding incorrectly, and were not also possessed 'wild type' HAT activity. Thus, the carboxystudied further.
terminal border of the HAT domain was defined by these mutants at amino acid 261. Next, we determined the ability of the above (series Separation of the HAT domain from the ADA2
2) mutants to interact with ADA2 using in vitro cointeraction domain in vitro immunoprecipitation, which previously was used to define The above data suggest that the minimal HAT domain of the region of interaction with ADA2 between amino acids GCN5 mapped between amino acids 170 and 253, while 254 and 350 of GCN5 (Candau and Berger, 1996) . Each the domain possessing full HAT activity mapped between mutant was co-translated in vitro with full-length ADA2. 95 and 350. We wished to map the carboxy-terminal All of the GCN5 mutants larger than 1-261 (GCN5 1-280 , border of the HAT domain more precisely to better 1-299 and 1-316 ) were immunoprecipitated using α-ADA2 delineate and ideally separate the region of HAT activity antibody ( Figure 4 ). However, GCN5 1-261 did not cofrom the region of interaction with ADA2. Therefore, we prepared a second series of deletion mutants with carboxyprecipitate with ADA2, indicating that the domain of Fig. 4 . Co-immunoprecipitations of ADA2 and GCN5 deletion mutants. Each GCN5 deletion mutant (series 2) was co-translated in vitro with ADA2 and immunoprecipitated with α-ADA2 antisera. 35 S-labeled proteins were visualized by autoradiography after 12% SDS-PAGE. in ϭ input and ppt ϭ precipitate. The side arrow indicates ADA2 protein and the bracket indicates GCN5 deletion peptides. Note the presence of a non-specific protein that migrates between GCN5 1-260 and GCN5 1-280 , which is likely to be an ADA2 degradation product.
growth of a GCN5 disruption strain was tested. The mutants were cloned into a yeast expression vector, and each one was transformed and restreaked onto minimal media. Wild-type GCN5 or vector alone served as positive and negative controls for growth in this assay ( Figure 5A ). The only deletion that maintained full growth complementation was GCN5 , which lacked the aminoterminal 95 amino acids. All other deletions resulted in complete or partial loss of growth complementation ( Figure 5A ). Deletion of the conserved subregion I ( Figure  1 ) of the HAT domain (GCN5 170-440 ) resulted in loss of (GCN5 1-350 ) caused partial loss of growth complementation in the GCN5 deletion strain (Marcus et al., 1994; Figure 5A) . Surprisingly, this mutant complemented ADA2 interaction is contained between amino acids 254 growth more poorly than the smaller peptides GCN5 1-280 , (Candau and Berger, 1996) and 280 of GCN5. Since the 1-299 or 1-316 , which is shown more clearly in the liquid HAT activity displayed by GCN5 1-261 was comparable growth assay ( Figure 5B ). Immunoblot analysis of the with full-length GCN5, the lack of GCN5 1-261 interaction mutants containing these deletions revealed that all were with ADA2 was not due to inappropriate folding. These comparable in stability with wild-type, with the exception results distinguished the carboxy-terminal border of the of the bromodomain deletion, which was partially unstable HAT domain (aa 261) from the carboxy-terminal border (data not shown). (Note that the strain used differed from of the ADA2 interaction domain (aa 280).
those used in previous studies; Marcus et al., 1996.) However, the partial instability of GCN5 1-350 did not seem Domains of GCN5 required for in vivo growth to account entirely for its poor growth complementation, complementation in the gcn5 -strain since the same mutant was indistinguishable from wildThree distinct functional regions have been identified type in other in vivo assays (see below). within GCN5. We have defined here the boundaries of Overall, these data indicate that critical regions of the HAT domain and the ADA2 interaction domain in vitro, GCN5 for growth complementation lie between amino and the bromodomain has been shown to be required for acids 95 and 280. full function of GCN5 in vivo (Marcus et al., 1994) . We wished to determine whether the HAT or other regions of Domains of GCN5 required for complementation GCN5 are required for in vivo function of GCN5.
of GAL4-VP16-mediated growth inhibition in the Genetic deletion of GCN5 resulted in defective colonial gcn5 -strain growth on minimal synthetic media (Marcus et al., 1994) .
We previously have shown that overexpression of GAL4-VP16 (Sadowski et al., 1988) , a chimeric activator comThus, the ability of the deletion mutants to complement . Growth inhibition of GAL4-VP16 in the presence of the GCN5 deletion mutants. The ability of the second series of the GCN5 deletion mutants to confer the slow growth phenotype in the presence of high copy plasmid expressing GAL4-VP16 is shown. GAL4-VP16 was co-transformed with the indicated GCN5 mutants into the gcn5 -strain. Transformants were plated onto minimal synthetic media and were grown at 30°C for 4 days. Full-length GCN5 (1-440) and vector alone were used as positive and negative controls.
posed of the GAL4 DNA binding domain and the transcriptional activation domain derived from the herpes simplex virus protein, VP16, results in strong growth inhibition in cells containing wild-type GCN5, and this inhibition is relieved when GCN5 is deleted (Marcus et al., 1994) . Growth inhibition by GAL4-VP16 may be caused by sequestration of essential transcription factors (Gill and Ptashne, 1988) by the potent VP16 activation domain, and was used as the basis for the genetic screen ) that led to the identification of adaptors ADA2, ADA3, GCN5 and ADA5. We used this growth complementation assay. GCN5 95-440 was similar Fig. 7 . Transcriptional activation in the presence of the GCN5 deletion mutants by the strong activator GAL4-VP16. The series 1 (A) and 2 (B) of GCN5 deletion mutants were co-transformed into PSY316Δgcn5, along with low copy plasmids expressing GAL4-VP16 and reporter pLGSD5 (Guarente et al., 1982) , containing bacterial lacZ driven by the GAL1-10 promoter. β-Gal activity was determined as units per mg of protein. Error bars represent the standard error about the mean from at least two independent experiments. to wild-type in both assays (data not shown). Mutants that and 254-440 ) were unable to complement. These results paralleled those obtained in the HAT assay, since the lacked portions of the HAT domain (GCN5 170-440 or GCN5 254-440 ) were unable to restore toxicity by GAL4-relative profiles of activation in vivo ( Figure 7A ) and HAT activity in vitro ( Figure 2C ) were similar, suggesting that VP16 (data not shown), just as they were unable to complement growth. All of the deletions carboxy-terminal HAT activity is necessary for transcriptional activation.
As before in the growth assay, the relative contributions to amino acid 280 (GCN5 1-280 , 1-299 , 1-316 and 1-350 ) complemented growth inhibition, while GCN5 1-261 and of HAT and ADA2 interaction could not be determined, since both functions were reduced in the GCN5 1-253 GCN5 1-253 did not (Figure 6 ), indicating that interaction with ADA2 is necessary for functional interaction with mutant. Thus, the second series of mutants was tested in the GAL4-VP16 transcription assay. Parallel to the growth GAL4-VP16, just as it was necessary for complementation of growth.
assay, loss of ADA2 interaction resulted in a completely defective protein (GCN5 1-261 ), even though it possessed The bromodomain mutant, GCN5 1-350 , behaved differently in each growth assay. In the GAL4-VP16 inhibition full HAT activity in vitro ( Figure 3B and C). Thus the HAT domain, on its own, was not sufficient for in vivo assay, the mutant was indistinguishable from wild-type ( Figure 6 ). In contrast, the mutant only partially compleactivity either in growth complementation or in transcriptional activation, and ADA2 interaction was also required. mented growth and, in fact, complemented more poorly than shorter mutants ( Figure 5A and B). This dual behavior One difference between the growth assay and the transcription assay was the effect of deleting the carboxywas seen in other experiments, as described below.
terminus to amino acid 280. These mutants (GCN5 1-350 , 1-316 , 1-299 and 1-280 ), which were similar to wild-type for Domains of GCN5 required for complementation of transcriptional activation in the gcn5 -strain activation by GAL4-VP16 ( Figure 7B ), were partially defective in growth, especially the bromodomain deletion We wished to identify domains of GCN5 required for transcriptional activation in vivo and, in particular, whether ( Figure 5 ). Failure to detect intermediate phenotypes in the transcription assay could be explained by the potency the HAT domain had a critical role in transcriptional activation. Activation by GAL4-VP16, containing the fullof the full-length VP16 activation domain, which could mask partial defects. In this case, weaker activation length VP16 activation domain (aa 413-490) (Triezenberg et al., 1988) , previously was shown to be reduced 7-to domains might reveal intermediate phenotypes of the GCN5 mutants. 10-fold in strains deleted for ADAs Piña et al., 1993) , including GCN5 (Marcus et al., 1994) .
To test this hypothesis, complementation of GAL4-VP16 470-490 (Barlev et al., 1995) was assayed with each We tested the ability of each GCN5 deletion mutant to complement transcriptional activation mediated by GAL4-of the deletion mutants. Previous results showed that this region of VP16 constitutes an activation subdomain, VP16 in a gcn5 -background.
A low copy plasmid expressing GAL4-VP16 was codisplaying 3-to 4-fold weaker activation than the fulllength VP16, but normal interaction with ADA2 in vitro transformed with a reporter containing bacterial lacZ driven by GAL4 binding sites, and wild-type GCN5 or (Barlev et al., 1995) . Indeed, GAL4-VP16 470-490 required GCN5 function in vivo, since its activity was reduced the deletion mutants. The results of β-gal assays from the first series of deletion mutants is shown in Figure 7A .
nearly 10-fold in the gcn5 -strain ( Figure 8A ). As was observed with the full-length VP16 activation domain, The GCN5 1-350 and GCN5 95-440 deletion mutants complemented the gcn5 -strain, since they exhibited levels of the deletions GCN5 1-261 and GCN5 1-253 were completely defective. In contrast to the complete complementation by transcription similar to wild-type GCN5. The other mutants, which contained further amino-or carboxythe intermediate peptides with full-length VP16, each peptide (GCN5 1-350 , 1-316 , 1-299 and 1-280 ) exhibited partial terminal deletions of GCN5 (GCN5 1-253 , 1-170 , 170-440 Both the HAT and ADA2 interaction domains are required for lexA-GCN5 activity in vivo The presence of the intrinsic HAT activity in GCN5 raises the question of whether the HAT catalytic domain can activate transcription if it is artificially targeted to a promoter, thus rendering it activation domain-independent. If the roles of activators and the ADA complex are to 'deliver' the HAT to promoters, then fusion of the HAT domain to a DNA binding domain should result in a protein capable of transcriptional activation. In contrast, if either activator or the ADA complex is required to acetylate nucleosomal histones, then additional domains may be required in addition to the HAT catalytic domain. To distinguish between these alternatives, full-length GCN5 or various GCN5 deletion mutants were genetically fused to the lexA DNA binding domain ( Figure 9A ). These were then transformed into yeast, and their ability to activate a lacZ reporter driven by lexA binding sites was determined.
LexA-GCN5 activated transcription 10-fold better than lexA alone ( Figure 9B ). The HAT domain was required for lexA-GCN5 activity, since deletion of it (lexA-GCN5 254-440 ) lowered activation nearly to background levels. However, lexA-GCN5 1-261 , containing only the HAT domain, was unable to activate. The addition of the ADA2 interaction domain allowed lexA-GCN5 1-280 to activate, in fact, 2-fold better than the full-length GCN5 fusion. The requirement for lexA-GCN5 to associate with ADA2 was also shown by complete loss of activity in ada2 -cells ( Figure 9C ). The level of lexA-GCN5 protein was comparable in ADA2 ϩ and ada2 -cells. Collectively, 
Discussion
along with plasmids expressing low-copy GAL4-p53 1-40 and reporter pLGSD5. β-Gal activity was determined as units per mg of protein.
Yeast GCN5 was originally identified as a regulatory
Error bars represent the standard error about the mean from at least two independent experiments. factor required for function of the yeast activator GCN4 (Georgakopoulos and Thireos, 1992) , and was isolated independently as a factor necessary for maximal transcripcomplementation, and, as in the growth complementation, tional activation by GAL4-VP16 (Marcus et al., 1994) . the bromodomain mutant was more defective than the GCN5 interacts with a second factor, ADA2, which was shorter peptides. isolated in the same genetic selection ; A second chimeric activator was also tested, GAL4-Marcus et al., 1994) . Recently, GCN5 has been shown to p53, that contained the amino terminal 1-40 amino acids possess histone acetyltransferase activity in vitro (Brownell of the p53 activation domain (Fields and Jang, 1990; , potentially linking transcriptional activation Farmer et al., 1992; Scharer and Iggo, 1992) fused to with the covalent modification of the amino-termini of GAL4. GAL4-p53 activation dropped~20-fold in the histones. In the present study, we have mapped the gcn5 -strain (R.Candau and S.L.Berger, submitted).
boundaries of the HAT domain of GCN5, and have shown GAL4-p53 1-40 showed the same profile of dependence that this domain is required for activity in vivo in several on GCN5 as did GAL4-VP16 470-490 , with intermediate independent assays. Our data suggest that the HAT domain, complementation by the shorter peptides GCN5 1-316 , while essential for activation in vivo, is not sufficient. and 1-280 , and even poorer complementation by GCN5 .
Rather, the ADA2 interaction domain in GCN5 is also Overall, these results demonstrate that the HAT domain, required for full activity. as well as the ADA2 interaction domain, are critical for GCN5Јs role in transcriptional activation. Furthermore, Critical elements of the HAT catalytic domain lie the carboxy-terminal region of GCN5, beyond the ADA2 between amino acids 170 and 250 interaction domain, was required for full activation by Mapping the HAT catalytic domain in vitro indicates that the full domain is encompassed within amino acids 95-weaker transcriptional activators, but not a strong activator. Transcriptional activation by lexA-GCN5. The indicated lexA-GCN5 deletion mutants, or lexA alone as negative control, were co-transformed in the gcn5 -strain along with a lexA reporter containing either one (YEP21) (Brent and Ptashne, 1985) or eight lexA binding sites (Candau et al., 1996) . β-Gal activity is shown relative to full-length GCN5. Error bars represent the standard error about the mean from two independent experiments. (C) Transcriptional activation by lexA-GCN5 in the ada2 -strain. Full-length lexA-GCN5 or lexA alone as negative control were co-transformed in PSY316 or PSY316Δgcn5 along with a lexA reporter containing either one or eight lexA binding sites. β-Gal activity is shown relative to full-length GCN5. Error bars represent the standard error about the mean from two independent experiments. 261, while a minimal domain lies between 170 and 253 ( Figure 10 ). These data support the notion that the most conserved portions of GCN5 (aa 120-253) constitute the HAT domain . We have suggested previously that His145 may comprise an essential residue of the active site. Since the minimal domain lies between 170 and 253, critical active site residues will probably lie within these boundaries.
Critical elements for in vivo activation lie between amino acids 95 and 280
In contrast to the mapping of the HAT domain (aa 95-261), an extended region of GCN5 was required for full in vivo function. A 20 amino acid region (to aa 280) beyond the carboxy-terminal boundary of the HAT domain (at aa 261) was crucial for growth and transcriptional activation by both GAL4-VP16 and GAL4-p53. Since immunoprecipitation of GCN5 by ADA2 also required sequences up to amino acid 280, ADA2 interaction appears an ADA complex including ADA3 (Horiuchi et al., 1995; Candau and Berger, 1996) and ADA5 (Marcus et al., However, the stronger activity of lexA-GCN5 1-280 compared with full-length lexA-GCN5 is consistent with the 1996), it is likely that GCN5 requires the ADA complex to acetylate nucleosomal histones and, thus, to activate presence of a repression domain. transcription in vivo. Whether acetylation of nucleosomal substrates occurs through subunit exchange of GCN5/ Targeting of GCN5 to a promoter, as well as interaction with ADA2, is required for function ADA subunits with defined sub-nucleosomal subunits, as has been proposed recently , remains in vivo We reasoned that if GCN5, and therefore the HAT domain, unknown, but is consistent with the involvement of ADA2 reported here.
requires targeting to promoters via interaction with DNAbound transcriptional activators (Wolffe and Pruss, 1996) , Elements between amino acids 95 and 170 that contribute to HAT activity also appeared to be crucial for fusion of GCN5 to a DNA binding domain should be active independently of interaction with bona fide function, since GCN5 170-440 (which had only 20% HAT activity) lacked the ability to function in vivo. Consistent activators. Indeed, lexA-GCN5 activated transcription, and this activation required the HAT domain of GCN5. with this result is the finding that the point mutation H145A in GCN5 reduces HAT activity 2-to 5-fold in all This is consistent with previous observations that activators associate with components of the ADA complex to target our in vitro assays (J.Z. and C.D.Allis, unpublished data). Thus, either GCN5 is extremely sensitive to partial loss the complex to promoter regions Barlev et al., 1995) . of HAT activity or additional functions localize to amino acids 95-170.
Furthermore, if the sole role of the ADA complex is to provide appropriate surfaces for protein-protein interaction with activation domains, then lexA-GCN5 should not The bromodomain was required for weak activator function in vivo, but not for strong activator require ADA2 or its ADA2 interaction domain for activity in vivo. Since lexA-GCN5, in the absence of ADA2, function Previous studies have shown an important role for the and lexA-GCN5 1-261 , lacking the ability to interact with ADA2, were both inactive, the ADA complex apparently bromodomain of GCN5 in vivo (Marcus et al., 1994) . Since HAT1, a cytoplasmic histone acetyltransferase, does has an additional function in vivo beyond interaction with activation domains. not contain a bromodomain (Kleff et al., 1995) , one possibility is that the bromodomain is required for access Why do both GCN5 and lexA-GCN5 require interaction with ADA2, and presumably the ADA complex, for of GCN5 to nucleosomal histones in the nucleus. However, the present study indicates that the bromodomain is not function in vivo? Since recombinant GCN5 acetylates 'free' histones, but not nucleosomal histones in vitro (Kuo likely to be a critical component in the acetylation of nucleosomal histones. First, the bromodomain was comet al., 1996; Yang et al., 1996) , it is likely that the ADA complex contributes critical determinants for interaction pletely dispensable for full HAT activity in vitro and activation by the strong activator GAL4-VP16. Second, with histones in their native nucleosomal state. Indeed, in both yeast (P.Grant and J.Workman, personal communicaweak activators required the bromodomain for full activity, but were less affected by bromodomain deletion tion) and Tetrahymena (J.Brownell and C.D.Allis, unpublished data) GCN5 is one component of multi-subunit compared with deletion of the HAT domain. Finally, lexA-GCN5 1-280 , which lacked the bromodomain, was a stronger complexes which are capable of acetylating nucleosomal histones. Further mutagenesis of GCN5, combined with activator than full-length lexA-GCN5. Taken together, these data suggest that the bromodomain is not involved analysis of native complexes, will clarify the mechanism of acetylation of nucleosomal substrates. directly in activation through nucleosomal histone acetylation, but may play a critical role in protein-protein interactions that are not detected in these assays. For
Materials and methods
example, we have detected an interaction between the bromodomain of human GCN5 (Candau et al., 1996) Yeast strains The trp1 derivatives of PSY316Δada2 and the p70 subunit of Ku autoantigen (N. Barlev and 3, and PSY316Δgcn5 (MATα ade2-101 Δhis3-S.L.Berger, unpublished data). The Ku autoantigen p70-200 leu2-3,112 lys2 ura3-52 trp1) have been described previously p80 heterodimer is the DNA binding component of the (Candau et al., 1996) . DNA-PK holoenzyme (for a review, see Jackson, 1996) .
Plasmids and deletion mutants
This interaction may be regulatory, as DNA-PK was found Plasmids were constructed using standard procedures (Ausubel et al., to phosphorylate and inhibit the HAT activity of human 1994).
GCN5 in vitro. A putative yeast homolog of Ku interacted
To generate the deletion mutants of GCN5 for in vitro translation, with yeast GCN5 (N. Barlev and S.L.Berger, unpublished fragments comprising residues 1-261, 1-280, 1-299 and 1-316 of GCN5 bearing a NotI restriction site at the 5Ј end and an EagI restriction site data), suggesting a conserved regulatory function of the at the 3Ј end were amplified by PCR. These fragments were digested bromodomain.
with EagI and inserted in SP64-NotI (Candau and Berger, 1996) opened Finally, we observed in several assays, including with NotI. growth complementation, weak activator function and For protein expression, pRSETB-NotI was generated by cloning a lexA-GCN5 activity, that the bromodomain deletion NotI linker in pRSETB (Invitrogen) digested with PvuII. The GCN5 deletion mutants were isolated from the corresponding SP64-NotI-GCN5 mutant GCN5 1-350 was less active than shorter mutants digested with EagI and then cloned into pRSETB-NotI as six-histidine (GCN5 1-316 , GCN5 1-299 and GCN5 The GCN5 deletion mutants were cloned into pPC87 by digestion of each SP64-NotI-GCN5 deletion mutant with EagI. Each GCN5 fragment
